Table 3.
Demographical and clinical data of the IBD patient cohort
| UC (n = 49) | CD (n = 14) | |
|---|---|---|
| Age (years) | ||
| - mean +/-SD | 39.6 +/- 13.5 | 32.4 +/- 13.1 |
| - range | 19-74 | 20-68 |
| Sex [male/female (n)] | 26/23 | 7/7 |
| Disease manifestation UC (n) | ||
| - rectum | 4 | |
| - rectosigmoid | 19 | |
| - including C. descendens (leftsided colitis) | 9 | |
| - pancolitis | 17 | |
| Disease manifestation CD (n) | ||
| - terminal ileum | 2 | |
| - terminal ileum + colon | 6 | |
| - colon only | 6 | |
| Endoscopic classification1 (n) | ||
| - mild inflammation | 15 | 4 |
| - moderate inflammation | 27 | 8 |
| - severe inflammation | 7 | 2 |
| Histopathologic examination (n) | ||
| - mild disease activity | 20 | 1 |
| - moderate disease activity | 23 | 8 |
| - severe disease activity | 6 | 1 |
| Anti-inflammatory therapy [AIT, (n)]2 | ||
| - no AIT | 14 | 1 |
| - AIT | 35 | 13 |
| substance class | ||
| - 5-ASA | 31 | 6 |
| - corticosteroids | 8 | 8 |
| - immunomodulators | 3 | 3 |
1 Macroscopic classification of the degree of inflammation was adjusted according to the Mayo endoscopic subscore [19].
2 Some patients received different substance classes, therefore the summation of patients in the category "substance class" exceeds the number of patients in the category "AIT". 5-ASA: 5-amino salicylic acid and its derivatives, immunomodulators: azathioprine and infliximab.